Literature DB >> 16048939

Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.

Robert A Larsen1, Madeline Bauer, Ann M Thomas, Alejandro Sanchez, Diane Citron, Meri Rathbun, Thomas S Harrison.   

Abstract

We conducted in vitro experiments to evaluate the susceptibility of a clinical isolate of Cryptococcus neoformans to a wide range of concentrations of fluconazole. In vitro susceptibility was tested using broth macrodilution methods modified to provide a numeric count of viable organisms. The association between the quantitative in vitro response and fluconazole drug concentrations was estimated using local nonparametric regression. Regression analysis was used to assess the correspondence between the in vitro fluconazole concentration-response curve and the murine dose-response curve observed in our previously reported murine model. The regression model was then used to predict the murine response. There was a strong correspondence between in vitro measures of response to fluconazole alone and the previously reported biologic effects seen in the mouse. In vitro antifungal drug susceptibility testing can reliably predict the murine response to fluconazole.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048939      PMCID: PMC1196263          DOI: 10.1128/AAC.49.8.3297-3301.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Antifungal susceptibility testing. New technology and clinical applications.

Authors:  M A Pfaller; W L Yu
Journal:  Infect Dis Clin North Am       Date:  2001-12       Impact factor: 5.982

Review 2.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Has antifungal susceptibility testing come of age?

Authors:  John H Rex; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2002-09-24       Impact factor: 9.079

4.  Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis.

Authors:  J C Ding; M Bauer; D M Diamond; M A Leal; D Johnson; B K Williams; A M Thomas; L Najvar; J R Graybill; R A Larsen
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing.

Authors:  O Lortholary; M Nicolas; S Soreda; L Improvisi; O Ronin; O Petitjean; B Dupont; M Tod; F Dromer
Journal:  J Antimicrob Chemother       Date:  1999-06       Impact factor: 5.790

6.  Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis.

Authors:  D M Diamond; M Bauer; B E Daniel; M A Leal; D Johnson; B K Williams; A M Thomas; J C Ding; L Najvar; J R Graybill; R A Larsen
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Correlation of fluconazole MICs with clinical outcome in cryptococcal infection.

Authors:  A I Aller; E Martin-Mazuelos; F Lozano; J Gomez-Mateos; L Steele-Moore; W J Holloway; M J Gutiérrez; F J Recio; A Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

8.  A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B.

Authors:  P Pitisuttithum; S Tansuphasawadikul; A J Simpson; P A Howe; N J White
Journal:  J Infect       Date:  2001-11       Impact factor: 6.072

9.  Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.

Authors:  D Andes; M van Ogtrop
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

10.  Early mycological treatment failure in AIDS-associated cryptococcal meningitis.

Authors:  P A Robinson; M Bauer; M A Leal; S G Evans; P D Holtom; D A Diamond; J M Leedom; R A Larsen
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

View more
  8 in total

1.  In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis.

Authors:  R A Larsen; M Bauer; A E Brouwer; A Sanchez; A M Thomas; A Rajanuwong; W Chierakul; S J Peacock; N Day; N J White; M G Rinaldi; T S Harrison
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

2.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis.

Authors:  Nathan P Wiederhold; Laura K Najvar; Edward P Garvey; Stephen R Brand; Xin Xu; Elizabeth A Ottinger; Asaf Alimardanov; Jim Cradock; Mark Behnke; William J Hoekstra; Robert J Schotzinger; Rosie Jaramillo; Marcos Olivo; William R Kirkpatrick; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.

Authors:  Hin Siong Chong; Rebecca Dagg; Richard Malik; Sharon Chen; Dee Carter
Journal:  J Clin Microbiol       Date:  2010-09-15       Impact factor: 5.948

5.  Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii.

Authors:  F E S Mendes; L V N Oliveira; E S Faria; D G Alvarenga; M R Pinto; C P Taborda; B M Soares; P S Cisalpino; D A Santos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-28       Impact factor: 3.267

6.  Cryptococcus neoformans: the model organism for yeast antifungal drug susceptibility testing.

Authors:  Madeline Bauer; Ann M Thomas; Robert A Larsen
Journal:  Mycopathologia       Date:  2012-02-10       Impact factor: 2.574

7.  Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.

Authors:  Ajay Sudan; Joanne Livermore; Susan J Howard; Zaid Al-Nakeeb; Andrew Sharp; Joanne Goodwin; Lea Gregson; Peter A Warn; Tim W Felton; John R Perfect; Thomas S Harrison; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

8.  Enhanced Killing and Antibiofilm Activity of Encapsulated Cinnamaldehyde against Candida albicans.

Authors:  Shahper N Khan; Shakir Khan; Jawed Iqbal; Rosina Khan; Asad U Khan
Journal:  Front Microbiol       Date:  2017-08-29       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.